Endothelin-receptor antagonists: Current and future perspectives

Drug Discovery Today

Volumn 5, Issue 10, 2000, Pages 455-464

  Ray, Abhijit ^a   Hegde, Laxminarayan G ^a   Chugh, Anita ^a   Gupta, Jang B ^a  

^a RANBAXY LABORATORIES LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ATRASENTAN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOSPORIN A; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; SITAXSENTAN;

ASTHMA; DRUG POTENCY; ERECTILE DYSFUNCTION; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; PROSTATE CANCER; PROSTATE CARCINOMA; PULMONARY HYPERTENSION; REVIEW;

EID: 0034307880     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(00)01557-9     Document Type: Review

References (64)

1. Yanagisawa M.et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
2. Battistini B.et al. Endothelin: a knock out in London. Trends Pharmacol. Sci. 16:1995;217-222.
3. Ferro C.J., Webb D.J. The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs. 51:1996;12-27.
4. Webb D.J., Strachan F.E. Clinical experience with endothelin antagonists. Am. J. Hypertens. 11:1998;71. S-79S.
5. Schiffrin E.L.et al. Clinical significance of endothelin in cardiovascular disease. Curr. Opin. Cardiol. 12:1997;354-367.
6. Goldie G.R., Henry P.J. Endothelins and asthma. Life Sci. 65:1999;1-15.
7. Doherty A.M. 1. Design and discovery of nonpeptide endothelin antagonists. Drug Discovery Today. 1:1996;60-69.
8. Haynes W.G., Webb D.J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 344:1994;852-854.
9. Weber C.et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin. Pharmacol. Ther. 60:1996;124-137.
10. Plumpton C.et al. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br. J. Pharmacol. 119:1996;311-314.
11. Lloyd I. Pharma Project (Version 2.1). 1999;PJB Publications Ltd.
12. Ihara M.et al. Biological profile of highly potent novel endothelin antagonists selective for ETA receptor. Life Sci. 50:1991;247-255.
13. Buchan K.W.et al. Characterization of three non-peptide endothelin receptor ligands using human cloned ETA and ETB receptors. Br. J. Pharmacol. 112:1994;1251-1257.
14. A receptor subtype in the anaesthetized rat: effect of BQ-123 on systemic haemodynamic responses. Eur. J. Pharmacol. 221:1992;315-324.
15. Clozel M.et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270:1994;228-235.
16. Schiffrin E.L.et al. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br. J. Pharmacol. 115:1995;1377-1381.
17. B receptors in canine coronary arteries. Circ. Res. 74:1994;105-114.
18. Zimmerman M.J. Endothelin in cerebral vasospasm. Neurosurg. Sci. 41:1997;139-151.
19. Karam H.et al. Role of endothelin in acute renal failure due to rhabdomyolysis in rats. J. Pharmacol. Exp. Ther. 274:1995;481-486.
20. Ohlstein E.H.et al. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 276:1996;609-615.
21. A-selective receptor antagonist. J. Pharmacol. Exp. Ther. 276:1996;473-481.
22. A receptor antagonist. J. Pharmacol. Exp. Ther. 272:1995;1124-1134.
23. Wu C.et al. Discovery of TBC 11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J. Med. Chem. 40:1997;1690-1697.
24. Baron F.C.et al. The endothelin receptor antagonist SB 217242 reduces cerebral focal ischemic brain injury. J. Cardiovasc. Pharmacol. 26:1995;S404-S407.
25. Tatlisumak T.et al. A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion: a diffusion and perfusion MRI study. Stroke. 29:1998;850-857.
26. Blezar E.L.et al. Early-onset but not late-onset endothelin- A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats. Hypertension. 33:1999;137-144.
27. Chen S.J.et al. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J. Cardiovasc. Pharmacol. 29:1997;713-725.
28. A receptor blockade in a rat model of radiocontrast-induced nephropathy. Renal Fail. 19:1997;753-761.
29. Burke S.E.et al. Selective antagonism of the ET(A) receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs. J. Cardiovasc. Pharmacol. 30:1997;33-41.
30. Nelson J.B.et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology. 53:1999;1063-1069.
31. Wu-Wong J.R.et al. 1. Endothelin receptor in benign prostatic hyperplastic cells. Binding and functional studies. Recept. Signal Transduction. 7:1997;165-175.
32. Nabokov A.V.et al. Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int. 55:1999;512-519.
33. Snapper J.R.et al. Role of endothelin in endotoxin-induced sustained pulmonary hypertension in sheep. Am. J. Respir. Crit. Care Med. 157:1998;81-88.
34. Freed M.I.et al. Pharmacokinetics and pharmacodynamics of SB 209670 an endothelin receptor antagonist: effects on the regulation of renal vascular tone. Clin. Pharmacol. Ther. 65:1999;473-482.
35. Weber C.et al. Multiple dose pharmacokinetics, safety, and tolerability of bosentan, and endothelin receptor antagonist in healthy male volunteers. Clin. Pharmacol. 39:1999;703-714.
36. Haynes W.G.et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 93:1996;1860-1870.
37. Kiowski W.et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
38. Sutsch G.et al. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc. Drugs Ther. 10:1997;717-725.
39. Sutsch G.et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 98:1998;2262-2268.
40. Krum H.et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. New Engl. J. Med. 338:1998;784-790.
41. Wenzel R.R.et al. Haemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation. 98:1998;2235-2240.
42. Jackson E.K., Garrison J.C. Renin and angiotensin. Hardman J.G.et al. Goodman and Gilman's The Pharmacological Basis of Therapeutics (IXth edn). 1996;733-758 MacMillan Publishing Co.
43. Crawford E.D.et al. Hormone refractory prostate cancer. Urology. 54:1999;1-7.
44. Nelson J.B.et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 56:1996;663-668.
45. Hsu J.Y., Pfahl M. ET-1 expression and growth inhibition of prostate cancer cells: a retinoid target with novel specificity. Cancer Res. 58:1998;4817-4822.
46. Rubin L.J. Consensus conference on primary pulmonary hypertension. Chest. 104:1993;236-250.
47. Giaid A.et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New Engl. J. Med. 328:1993;1732-1739.
48. Opgenorth T. Endothelin receptor antagonism. August J.T.et al. Advances in Pharmacology (Vol. 33). 1995;1-65 Academic Press.
49. Ray A.et al. Thrombin receptor: a novel target for antiplatelet drug development. Thromb. Res. 87:1998;37-50.
50. Willette R.N.et al. Nonpeptide endothelin receptor antagonists. VIII: attentuation of acute hypoxia-induced pulmonary hypertension in the dog. J. Pharmacol. Exp. Ther. 28:1997;695-701.
51. Lopez-Farre A.et al. A role for endothelin in the maintenance of postischemic renal failure in rat. J. Physiol. 444:1991;513-522.
52. Mino N.et al. Protective effect of selective endothelin receptor antagonist, BQ 123, in ischemic acute renal failure in rats. Eur. J. Pharmacol. 221:1992;77-83.
53. Kusumoto K.et al. Effects of a new endothelin antagonist, TAK 044, on post ischemic acute renal failure in rats. Life Sci. 55:1994;301-310.
54. Brooks D.P.et al. Effect of the endothelin receptor antagonist, (±) SB 209670 and BQ 123, on ischemia induced acute renal failure (ARF) in the dog. FASEB J. 8:1994;A585.
55. Goldstein D.J.et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation. 63:1997;664-668.
56. Fisher N.C.et al. 1. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation. 66:1998;59-66.
57. Benigni A.et al. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int. 55:1999;674-685.
58. Fogo A.et al. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int. 42:1992;770-774.
59. Binet I.et al. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. 57:2000;224-231.
60. Andersson K.E., Wagner G. Physiology of penile erection. Physiol. Rev. 75:1995;191-236.
61. Burnett A.L.et al. Nitric oxide a physiological mediator of penile erection. Science. 257:1992;401-403.
62. Jarow J.P.et al. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J. Urol. 162:1999;722-725.
63. Khan M.A.et al. Endothelin and erectile dysfunction: a target for pharmacological intervention. Exp. Opin. Invest. Drugs. 7:1998;1759-1767.
64. Miyauchi T., Goto K. Heart failure and endothelin receptor antagonists. Trends Pharmacol. Sci. 20:1999;210-217.